publication date: Jun. 27, 2014

James Downing named CEO of St. Jude

JAMES DOWNING was named CEO of St. Jude Children’s Research Hospital, effective July 15. Downing most recently has served as deputy director, executive vice president and scientific director of the hospital.

His primary focus as CEO will be to oversee an expansion of the hospital’s clinical, research and infrastructure programs.

He succeeds William Evans, retiring from the position after 10 years and returning full time to his long-standing pharmacogenomics research program at St. Jude.

Downing’s work as a genome sequencing pioneer, overseeing the Pediatric Cancer Genome Project, was recognized in 2012 by TIME magazine as one of the Top 100 new scientific discoveries.

Downing outlined his vision for St. Jude’s expansion, which includes: growing number of patients treated on the St. Jude campus; expanding the pediatric solid tumors treatment and research programs; expanding the International Outreach Program; incorporating genomic analyses into clinical work using the Pediatric Cancer Genome Project; growing the number of patients enrolled on the St. Jude LIFE long-term follow-up survivor study; and establishing a formalized patient advocacy consortium.

was named a recipient of the Chancellor’s Health Fellowship by MD Anderson Cancer Center.

Chin, chair of the Department of Genomic Medicine, was recognized for development of a patient-centric oncology care delivery system initiated in late 2012. She is the wife of MD Anderson President Ronald DePinho.

During her one-year appointment as a fellow, she will coordinate the planning and development of a similar effort focusing on management of diabetes in South Texas. Chin will collaborate with … Continue reading 40-26 The Cancer Letter In Brief – FDA Approvals

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.